Medtronic to Acquire CathWorks

February 5, 2026—Medtronic announced it will exercise its option to acquire CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease (CAD) with its fractional flow reserve (FFR) diagnostic technology.

In 2022, Medtronic announced a strategic partnership with a copromotion agreement for the CathWorks FFRangio system in the United States, Europe, and Japan, where it is commercially available.

According to Medtronic, the acquisition is valued at up to $585 million with potential undisclosed earn-out payments after the acquisition. The deal is pending clearance from the US Federal Trade Commission. This phase is expected to be completed by the end of Medtronic’s fiscal year 2026, subject to applicable regulatory approvals and other customary closing conditions. At the date of the acquisition closing, CathWorks will become a part of Medtronic.

Medtronic and CathWorks will continue to operate independently until the deal is closed, noted the company.

Jason Weidman, Senior Vice President and President of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic, commented on the intended acquisition in the press release.

“Medtronic is thrilled to move forward with our option to officially acquire CathWorks,” stated Weidman. “Through our copromotion agreement, we’ve seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient’s journey, from diagnosis to treatment. This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care.”